You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, December 2016
|
| DOI | 10.1186/s40425-016-0198-x |
| Pubmed ID | |
| Authors |
Douglas G. McNeel, Neil H. Bander, Tomasz M. Beer, Charles G. Drake, Lawrence Fong, Stacey Harrelson, Philip W. Kantoff, Ravi A. Madan, William K. Oh, David J. Peace, Daniel P. Petrylak, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Mark N. Stein, Johannes Vieweg, James L. Gulley |
| Abstract |
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being investigated in late-stage clinical trials for the management of advanced prostate cancer. Therefore, the Society for Immunotherapy of Cancer (SITC) convened a multidisciplinary panel, including physicians, nurses, and patient advocates, to develop consensus recommendations for the clinical application of immunotherapy for prostate cancer patients. To do so, a systematic literature search was performed to identify high-impact papers from 2006 until 2014 and was further supplemented with literature provided by the panel. Results from the consensus panel voting and discussion as well as the literature review were used to rate supporting evidence and generate recommendations for the use of immunotherapy in prostate cancer patients. Sipuleucel-T, an autologous dendritic cell vaccine, is the first and currently only immunotherapeutic agent approved for the clinical management of metastatic castrate resistant prostate cancer (mCRPC). The consensus panel utilized this model to discuss immunotherapy in the treatment of prostate cancer, issues related to patient selection, monitoring of patients during and post treatment, and sequence/combination with other anti-cancer treatments. Potential immunotherapies emerging from late-stage clinical trials are also discussed. As immunotherapy evolves as a therapeutic option for the treatment of prostate cancer, these recommendations will be updated accordingly. |
X Demographics
The data shown below were collected from the profiles of 35 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 15 | 43% |
| Mexico | 2 | 6% |
| United Kingdom | 1 | 3% |
| Switzerland | 1 | 3% |
| France | 1 | 3% |
| Brazil | 1 | 3% |
| Spain | 1 | 3% |
| Italy | 1 | 3% |
| Unknown | 12 | 34% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 23 | 66% |
| Practitioners (doctors, other healthcare professionals) | 9 | 26% |
| Scientists | 2 | 6% |
| Science communicators (journalists, bloggers, editors) | 1 | 3% |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 66 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 20% |
| Student > Bachelor | 6 | 9% |
| Professor | 5 | 8% |
| Student > Ph. D. Student | 5 | 8% |
| Professor > Associate Professor | 4 | 6% |
| Other | 13 | 20% |
| Unknown | 20 | 30% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 38% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Immunology and Microbiology | 4 | 6% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Agricultural and Biological Sciences | 1 | 2% |
| Other | 6 | 9% |
| Unknown | 23 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 504. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 January 2021.
All research outputs
#52,026
of 25,734,859 outputs
Outputs from Journal for Immunotherapy of Cancer
#7
of 3,498 outputs
Outputs of similar age
#1,112
of 425,121 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 31 outputs
Altmetric has tracked 25,734,859 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,498 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.8. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 425,121 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 93% of its contemporaries.